Novo Nordisk A/S (NVO) Given Sell Rating at Barclays

Barclays reissued their sell rating on shares of Novo Nordisk A/S (NYSE:NVO) in a research report released on Tuesday morning.

A number of other analysts have also issued reports on NVO. Bank of America lowered shares of Novo Nordisk A/S from a buy rating to a neutral rating in a research note on Monday, October 8th. Guggenheim initiated coverage on shares of Novo Nordisk A/S in a research note on Monday, October 8th. They issued a buy rating for the company. Zacks Investment Research lowered shares of Novo Nordisk A/S from a buy rating to a sell rating in a research note on Wednesday, October 10th. Kepler Capital Markets restated a hold rating on shares of Novo Nordisk A/S in a research note on Thursday, October 18th. Finally, ValuEngine upgraded shares of Novo Nordisk A/S from a sell rating to a hold rating in a research note on Saturday, October 27th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $52.31.

Shares of NVO traded down $0.02 during mid-day trading on Tuesday, reaching $48.78. 492,467 shares of the stock traded hands, compared to its average volume of 1,463,645. The firm has a market capitalization of $118.63 billion, a P/E ratio of 19.36, a P/E/G ratio of 2.28 and a beta of 0.68. Novo Nordisk A/S has a 12-month low of $41.23 and a 12-month high of $54.56.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Friday, February 1st. The company reported $0.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.03). The company had revenue of $4.55 billion during the quarter, compared to the consensus estimate of $4.36 billion. Novo Nordisk A/S had a return on equity of 81.52% and a net margin of 34.67%. As a group, analysts forecast that Novo Nordisk A/S will post 2.58 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. Advisor Partners LLC increased its stake in Novo Nordisk A/S by 2.7% during the fourth quarter. Advisor Partners LLC now owns 12,634 shares of the company’s stock valued at $582,000 after purchasing an additional 338 shares during the last quarter. Dorsey & Whitney Trust CO LLC increased its stake in Novo Nordisk A/S by 6.7% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 6,727 shares of the company’s stock valued at $310,000 after purchasing an additional 420 shares during the last quarter. Winslow Evans & Crocker Inc. increased its stake in Novo Nordisk A/S by 0.8% during the fourth quarter. Winslow Evans & Crocker Inc. now owns 54,892 shares of the company’s stock valued at $2,530,000 after purchasing an additional 452 shares during the last quarter. Raymond James Trust N.A. increased its stake in Novo Nordisk A/S by 3.8% during the fourth quarter. Raymond James Trust N.A. now owns 14,206 shares of the company’s stock valued at $655,000 after purchasing an additional 519 shares during the last quarter. Finally, Brookstone Capital Management increased its stake in Novo Nordisk A/S by 8.0% during the fourth quarter. Brookstone Capital Management now owns 7,221 shares of the company’s stock valued at $333,000 after purchasing an additional 535 shares during the last quarter. Hedge funds and other institutional investors own 6.85% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Recommended Story: What are trading strategies for the 52-week high/low?

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply